[Immunomodulating action of blood component therapy in cancer patients].
The influence of blood-component therapy on the immune system in cancer patients (non-Hodgkin's lymphoma-33; intestinal adenocarcinoma-15) has been evaluated. Blood transfusions were found to change the activity of such components and factors of the immune system as B-lymphocytes, T-suppressors, tumor necrosis and interleukin-1, without major reactions of antitumor immunity being inhibited. Initial immunological status appeared to be a very important factor of immune processes. It is suggested that leukocyte-free blood alone be used for transfusions since leukocytes are suspected of producing an immuno-suppressive effect.
Zhiburt
E B
EB
Military Medical Academy, St.Petersburg.
D000230:Adenocarcinoma / Q000276:immunology* / Q000628:therapy; D000368:Aged; D016913:Blood Component Transfusion / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000276:immunology* / Q000628:therapy; D007962:Leukocytes; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
Immunomoduliruiushchee deĭstvie gemokomponentnoĭ terapii u onkologicheskikh patsientov.